News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,243 Results
Type
Article (41194)
Company Profile (264)
Press Release (685769)
Multimedia
Podcasts (88)
Webinars (20)
Section
Business (204771)
Career Advice (2028)
Deals (35559)
Drug Delivery (126)
Drug Development (81467)
Employer Resources (173)
FDA (16478)
Job Trends (14969)
News (346665)
Policy (32748)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2592)
Accelerated approval (43)
Adcomms (25)
Allergies (164)
Alliances (49577)
ALS (194)
Alzheimer's disease (1753)
Antibody-drug conjugate (ADC) (389)
Approvals (16815)
Artificial intelligence (607)
Autoimmune disease (234)
Automation (51)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (207)
Biotechnology (174)
Bladder cancer (179)
Brain cancer (66)
Breast cancer (694)
Cancer (5423)
Cardiovascular disease (452)
Career advice (1718)
Career pathing (41)
CAR-T (305)
CDC (54)
Celiac Disease (2)
Cell therapy (808)
Cervical cancer (43)
Clinical research (70340)
Collaboration (1952)
Company closure (4)
Compensation (1301)
Complete response letters (74)
COVID-19 (2732)
CRISPR (100)
C-suite (1023)
Cystic fibrosis (149)
Data (7191)
Decentralized trials (3)
Denatured (26)
Depression (154)
Dermatology (69)
Diabetes (553)
Diagnostics (6851)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (300)
Drug pricing (195)
Drug shortages (31)
Duchenne muscular dystrophy (267)
Earnings (91142)
Editorial (61)
Employer branding (21)
Employer resources (152)
Events (118565)
Executive appointments (1046)
FDA (19977)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (32)
Funding (1646)
Gene editing (214)
Generative AI (54)
Gene therapy (657)
GLP-1 (1024)
Government (4705)
Grass and pollen (6)
Guidances (400)
Healthcare (18958)
HIV (76)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (276)
Immuno-oncology (85)
Indications (163)
Infectious disease (3056)
Inflammatory bowel disease (201)
Inflation Reduction Act (14)
Influenza (132)
Intellectual property (277)
Interviews (316)
IPO (16652)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (18)
Labor market (94)
Layoffs (556)
Leadership (35)
Legal (7951)
Liver cancer (98)
Longevity (29)
Lung cancer (724)
Lymphoma (411)
Machine learning (54)
Management (59)
Manufacturing (953)
MASH (178)
Medical device (13873)
Medtech (13955)
Mergers & acquisitions (20087)
Metabolic disorders (1426)
mRNA (178)
Multiple sclerosis (176)
NASH (17)
Neurodegenerative disease (385)
Neuropsychiatric disorders (97)
Neuroscience (3168)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4525)
Now hiring (74)
Obesity (672)
Opinion (279)
Ovarian cancer (196)
Pain (235)
Pancreatic cancer (263)
Parkinson's disease (345)
Partnered (33)
Patents (562)
Patient recruitment (613)
Peanut (60)
People (59340)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21918)
Phase 2 (30974)
Phase 3 (23058)
Pipeline (7409)
Policy (306)
Postmarket research (2566)
Preclinical (9300)
Press Release (64)
Prostate cancer (278)
Psychedelics (49)
Radiopharmaceuticals (310)
Rare diseases (1001)
Real estate (5961)
Recruiting (70)
Regulatory (25069)
Reports (54)
Research institute (2408)
Resumes & cover letters (353)
Rett syndrome (33)
RNA editing (18)
RSV (87)
Schizophrenia (167)
Series A (271)
Series B (205)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3627)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (60)
Vaccines (1065)
Venture capital (99)
Weight loss (430)
Women's health (113)
Worklife (20)
Date
Today (140)
Last 7 days (578)
Last 30 days (2611)
Last 365 days (30071)
2026 (8975)
2025 (30171)
2024 (35212)
2023 (40075)
2022 (51175)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (738)
Alabama (91)
Alaska (7)
Arizona (333)
Arkansas (14)
Asia (39513)
Australia (6470)
California (12438)
Canada (3575)
China (1254)
Colorado (534)
Connecticut (536)
Delaware (375)
Europe (85351)
Florida (1881)
Georgia (400)
Hawaii (3)
Idaho (62)
Illinois (987)
India (84)
Indiana (573)
Iowa (22)
Japan (503)
Kansas (129)
Kentucky (46)
Louisiana (38)
Maine (75)
Maryland (1500)
Massachusetts (8889)
Michigan (348)
Minnesota (685)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (137)
New Hampshire (83)
New Jersey (3314)
New Mexico (28)
New York (3285)
North Carolina (1581)
North Dakota (8)
Northern California (6171)
Ohio (373)
Oklahoma (23)
Oregon (41)
Pennsylvania (2520)
Puerto Rico (28)
Rhode Island (50)
South America (1112)
South Carolina (82)
South Dakota (2)
Southern California (4891)
Tennessee (201)
Texas (1968)
United States (44097)
Utah (374)
Vermont (1)
Virginia (295)
Washington D.C. (80)
Washington State (999)
West Virginia (4)
Wisconsin (119)
Wyoming (2)
727,243 Results for "ocugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 22, 2026
·
3 min read
Press Releases
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 26, 2026
·
3 min read
Press Releases
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 9, 2026
·
3 min read
Press Releases
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
·
13 min read
Press Releases
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
April 1, 2026
·
7 min read
Press Releases
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
January 9, 2026
·
3 min read
Press Releases
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 2, 2026
·
7 min read
Press Releases
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
March 23, 2026
·
3 min read
Press Releases
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
March 24, 2026
·
8 min read
Press Releases
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
February 18, 2026
·
2 min read
1 of 72,725
Next
